Vendor, Carlsbad, CA
Arisan Therapeutics Inc.
UEI PYRKTQPNVJZ8, CAGE 616D2
2 awards and $2,933,547 obligated between November 18, 2025 and September 30, 2026, 100% under full and open competition, against 13.5 offers on average where reported. 11 of the awards trace back to a SAM.gov solicitation on this site.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,933,547 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Hear when Arisan Therapeutics Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Arisan Therapeutics Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 2
- Obligated so far
- $2,933,547
- Soonest
- December 31, 2026
The 2 contracts, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,369,442 |
| Westat, Inc.Rockville, MD | $760,724,225 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93026C00012Definitive Contract, July 29, 2026, Full and Open Competition, 20 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | To Develop a Therapeutic Small Molecule Viral Entry Inhibitor as a Medical Countermeasure for Filovirus Infection.NAICS 541715, PSC AN12 | $2,933,547 |
| 75N93023C00051Definitive Contract, November 18, 2025, Full and Open Competition, 7 offers | National Institutes of Health NiaidNational Institutes of Health | To Conduct Non-Clinical Good Laboratory Practice (Glp) in Vivo Genotoxicity and Reproductive Toxicology and GLP Development and ReproductiveNAICS 541715, PSC AN12 | $0 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 4 across 2 awards